Karl-Ernst Jeismann/Peter Lundgreen(Hrsg.): Handbuch der deutschen Bildungsgeschichte. Band III. 1800-1870: Von der Neuordnung Deutschlands bis zur Gründung des Deutschen Reiches. München: Beck 1987 […] [Sammelrezension]

Sammelrezension von: 1. Karl-Ernst Jeismann/Peter Lundgreen(Hrsg.): Handbuch der deutschen Bildungsgeschichte. Band III. 1800-1870: Von der Neuordnung Deutschlands bis zur Gründung des Deutschen Reiches. München: Beck 1987, 443 S. 2. Dieter Langewiesche/Hehiz-Elmar Tenorth (Hrsg.): Handbuch der deutschen Bildungsgeschichte. Band V. 1918-1945: Die Weimarer Republik und die nationalsozialistische Diktatur. München: Beck 1989. 470 S.

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

Purpose: Matrix metalloproteinases (MMPs) degrade extracellular proteins and facilitate tumor growth, invasion, metastasis, and angiogenesis. This trial was undertaken to determine the effect of prinomastat, an inhibitor of selected MMPs, on the survival of patients with advanced non-small-cell lung cancer (NSCLC), when given in combination with gemcitabine-cisplatin chemotherapy. Patients and Methods: Chemotherapy-naive patients were randomly assigned to receive prinomastat 15 mg or placebo twice daily orally continuously, in combination with gemcitabine 1,250 mg/m2 days 1 and 8 plus cisplatin 75 mg/m2 day 1, every 21 days for up to six cycles. The planned sample size was 420 patients. Results: Study results at an interim analysis and lack of efficacy in another phase III trial prompted early closure of this study. There were 362 patients randomized (181 on prinomastat and 181 on placebo). One hundred thirty-four patients had stage IIIB disease with T4 primary tumor, 193 had stage IV disease, and 34 had recurrent disease (one enrolled patient was ineligible with stage IIIA disease). Overall response rates for the two treatment arms were similar (27% for prinomastat v 26% for placebo; P = .81). There was no difference in overall survival or time to progression; for prinomastat versus placebo patients, the median overall survival times were 11.5 versus 10.8 months (P = .82), 1-year survival rates were 43% v 38% (P = .45), and progression-free survival times were 6.1 v 5.5 months (P = .11), respectively. The toxicities of prinomastat were arthralgia, stiffness, and joint swelling. Treatment interruption was required in 38% of prinomastat patients and 12% of placebo patients. Conclusion: Prinomastat does not improve the outcome of chemotherapy in advanced NSCLC. © 2005 by American Society of Clinical Oncology.

SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer : phase III results

Background: This open-label, randomised phase III study was designed to further investigate the clinical activity and safety of SRL172 (killed Mycobacterium vaccae suspension) with chemotherapy in the treatment of non-small-cell lung cancer (NSCLC). Patients and methods: Patients were randomised to receive platinum-based chemotherapy, consisting of up to six cycles of MVP (mitomycin, vinblastine and cisplatin or carboplatin) with (210 patients) or without (209 patients) monthly SRL172. Results: There was no statistical difference between the two groups in overall survival (primary efficacy end point) over the course of the study (median overall survival of 223 days versus 225 days; P = 0.65). However, a higher proportion of patients were alive at the end of the 15-week treatment phase in the chemotherapy plus SRL172 group (90%), than in the chemotherapy alone group (83%) (P = 0.061). At the end of the treatment phase, the response rate was 37% in the combined group and 33% in the chemotherapy alone group. Patients in the chemotherapy alone group had greater deterioration in their Global Health Status score (-14.3) than patients in the chemotherapy plus SRL172 group (-6.6) (P = 0.02). Conclusion: In this non-placebo controlled trial, SRL172 when added to standard cancer chemotherapy significantly improved patient quality of life without affecting overall survival times. © 2004 European Society for Medical Oncology.

Prognostic factors in patients with advanced non-small cell lung cancer : data from the phase III FLEX study

The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). In the FLEX intention to treat (ITT) population, we investigated the prognostic significance of particular baseline characteristics. Individual patient data from the treatment arms of the ITT population of the FLEX study were combined. Univariable and multivariable Cox regression models were used to investigate variables with potential prognostic value. The ITT population comprised 1125 patients. In the univariable analysis, longer median survival times were apparent for females compared with males (12.7 vs 9.3 months); patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 compared with 1 compared with 2 (13.5 vs 10.6 vs 5.9 months); never smokers compared with former smokers compared with current smokers (14.6 vs 11.1 vs 9.0); Asians compared with Caucasians (19.5 vs 9.6 months); patients with adenocarcinoma compared with squamous cell carcinoma (12.4 vs 9.3 months) and those with metastases to one site compared with two sites compared with three or more sites (12.4 months vs 9.8 months vs 6.4 months). Age (<65 vs ≥65 years), tumor stage (IIIB with pleural effusion vs IV) and percentage of tumor cells expressing EGFR (<40% vs ≥40%) were not identified as possible prognostic factors in relation to survival time. In multivariable analysis, a stepwise selection procedure identified age (<65 vs ≥65 years), gender, ECOG PS, smoking status, region, tumor histology, and number of organs involved as independent factors of prognostic value. In summary, in patients with advanced NSCLC enrolled in the FLEX study, and consistent with previous analyses, particular patient and disease characteristics at baseline were shown to be independent factors of prognostic value. The FLEX study is registered with ClinicalTrials.gov, number NCT00148798. © 2012 Elsevier Ireland Ltd.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) : an open-label randomised phase III trial

Background: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer. Methods: In a multinational, multicentre, open-label, phase III trial, chemotherapy-naive patients (≥18 years) with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer were randomly assigned in a 1:1 ratio to chemotherapy plus cetuximab or just chemotherapy. Chemotherapy was cisplatin 80 mg/m 2 intravenous infusion on day 1, and vinorelbine 25 mg/m 2 intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles. Cetuximab-at a starting dose of 400 mg/m 2 intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m 2 over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity had occurred. The primary endpoint was overall survival. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00148798. Findings: Between October, 2004, and January, 2006, 1125 patients were randomly assigned to chemotherapy plus cetuximab (n=557) or chemotherapy alone (n=568). Patients given chemotherapy plus cetuximab survived longer than those in the chemotherapy-alone group (median 11·3 months vs 10·1 months; hazard ratio for death 0·871 [95% CI 0·762-0·996]; p=0·044). The main cetuximab-related adverse event was acne-like rash (57 [10%] of 548, grade 3). Interpretation: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer. Funding: Merck KGaA. © 2009 Elsevier Ltd. All rights reserved.

Der Orden Pour le Mérite für Wissenschaften und Künste von 1842 bis 1983.

A brochure, listing all members of the order, 1842-1983. A typescript adds members until 1985 and lists Jewish members, 1842-1981.

Evaluación del rendimiento pesquero potencial de la República Argentina: III. Edad y crecimiento de peces 1

Age and growth of populations of three fish species from sixteen lakes and reservoirs situated in the Patagonian Andean and the Patagonian Plateau Region (Argentina) were studied. They included two native species, the Patagonian smallmouth perch. (Percichthys trucha) and the Patagonian silverside (Patagonina hatcheri) and the introduced rainbow trout (Oncorhynchus mykiss). For the three species backcalculated lenght at age was obtained from scale readings. Von Bertalanffy growth curves were usually adjusted to data. For the three species, faster growth was related with lake productivity. (Document contains 38 pages.)

Abbildungen zur naturgeschichte brasiliens : herausgegeben Von Maximilian, Prinzen Von Wied-Neuwied = Recueil de Planches coloriées d'animaux Du Brésil / publie par S.A.S. le Prince Maximilien de Wied-Neuwied

Abbildungen zur naturgeschichte brasiliens é uma magnífica obra publicada em fascículos, cada um deles contendo seis lâminas e seis folhas de texto. As estampas, coloridas, foram gravadas em metal e o texto explicativo apresenta-se em alemão e francês. As gravuras representam espécies da fauna brasileira identificadas pelo autor durante a expedição científica que, juntamente com os naturalistas Georg Freyreiss e Friedrich Sellow, empreendeu ao brasil entre 1815 e 1817. Segundo Borba de Moraes trata-se de edição "muito rara nos dias de hoje".

Gegenüberstellung von mathematisch-physikalischer Modellierung und Messungen an geschleppten fischereitechnischen Systemen

When drafting a new model of a towed technical system for fisheries (trawl, towed TV gear or similar), and also when measuring an existing and already tested system it is not easy to foresee of practical behaviour, which depends of various parameters. The measuring programme for recording all data needs a lot of time and money, and also has some limitations. Therefore we developed for such systems mathematical-physical models, which allow a complex calculation. Their real value, however, results only from practical verification. During the cruise no. 222 of “Walther Herwig III” in November 2000 comparative investigations for 2concrete systems were carried out. This was done in cooperation with the University in Rostock, where such models are being developed and computerized. One of the systems mesasured was a pelagic herring trawl and the other one the towed TV gear for underwater observations of the Institute for Fishery Technology and Fish Quality. The correspondence between model calculation and measurements was very high for both systems.

Sensibilität von Seefischen an Bord. Teil 2: Demersale und pelagische Fischarten aus Schleppnetzfängen in der Nord- und Ostsee

The sensitiveness of different demersal and pelagic fish species of 70 hauls in the North and Baltic Sea in water depths of 60 to 250 m and 15 to 80 m, respectively, amount of catch of 100 to 3500 kg and trawling times of 0,5 to 6 h on board of the FRV “Walther Herwig III” was investigated. Some demersal fish species , e.g. saithe (Pollachius virens), were even still sensitive, when caught at a water depth of 250 m at a trawling time of 1,5 h. Generally the number of sensitive fishes was reduced with increasing water depth, amount of catch, trawling time and following storage of the catch on board. Among demersal fishes the species without swimbladder and flat fishes were clearly more resistent to mechanical stress. On the contrary, pelagic fish species were generally less robust. After trawling times of 2 h no sensitive animals were observed. In some fisheries there are mixed catches of demersal and pelagic fish species with different sensitiveness. In commercial fisheries, there is therefore – under animal welfare aspects – for the time being, no prospect for an improvement of the catching and slaughtering procedure on board